<DOC>
	<DOC>NCT03036280</DOC>
	<brief_summary>The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat (proposed international nonproprietary name [pINN]) (E2609).</brief_summary>
	<brief_title>A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including: 1. Mini Mental State Examination score equal to or greater than 24 2. Clinical Dementia Rating (CDR) global score of 0.5 3. CDR Memory Box score of 0.5 or greater Impaired episodic memory confirmed by a list learning task Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography (PET) or cerebrospinal fluid assessment or both Study partner able to support the participant for duration of the study Females who are breastfeeding or pregnant at Screening or Baseline. Females of childbearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD Participants with a history of seizures within 5 years of Screening History of transient ischemic attacks or stroke within 12 months of Screening Psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, delusions, etc.) â€¢ Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years Have any contraindications to magnetic resonance imaging (MRI) scanning or Have lesions that could indicate a dementia diagnosis other than AD on brain MRI Exhibit other significant pathological findings on brain MRI Participants who have a history of moderate to severe hepatic impairment (eg, ChildPugh Class B or C) Results of laboratory tests conducted during Screening that are outside the following limits: Absolute lymphocyte count below the LLN Thyroid stimulating hormone above normal range Abnormally low Vitamin B12 levels Participants at risk of increased risk of infection Have received any live vaccine in the 3 months before randomization Any chronic inflammatory disease that is not adequately controlled or that requires systemic or ocular immunosuppressive or immunomodulatory therapy Any other clinically significant abnormalities Severe visual or hearing impairment A prolonged QTc interval (QTcF greater than 450 milliseconds [ms]) Malignant neoplasms within 5 years of Screening Known or suspected history of drug or alcohol abuse Taking prohibited medications, which must be reviewed with the Investigator Have participated in a recent clinical study Note: Other protocoldefined Inclusion/Exclusion Criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>E2609</keyword>
	<keyword>elenbecestat</keyword>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>Early Alzheimer's Disease</keyword>
	<keyword>Prodromal Alzheimer's Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Dementia, Alzheimer's type</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>MissionAD2</keyword>
</DOC>